XML 231 R23.htm IDEA: XBRL DOCUMENT
v3.25.0.1

Technology Transfer Agreement | 12 Months Ended
--- | ---
Dec. 31, 2024
Technology Transfer Agreement [Abstract] |
Technology Transfer Agreement | Technology Transfer Agreement Impilo Therapeutics In July 2023, the Company entered into a technology transfer agreement with Impilo Therapeutics (“Impilo”) under which the Company transferred its rights to its tumor penetrating nanocomplex (TPN) platform to Impilo. As consideration for the technology transfer, Impilo issued a total of 766,000 shares of its pre-seed preferred stock to the Company. On October 3, 2023 in connection with the Sanford Burnham Prebys license agreement (Note 16) Impilo cancelled the original stock certificate for 766,000 shares and reissued 574,500 shares of its pre-seed preferred stock to the Company. On March 15, 2024, the Company purchased a Simple Agreement for Future Equity ("SAFE") from Impilo for $100 thousand. On July 12, 2024, the Company purchased an additional SAFE from Impilo for $30 thousand. As of December 31, 2024 and December 31, 2023 the Company owned 38.6% of Impilo. These investments were expensed under the equity method of accounting for the year ended December 31, 2024 in other expense, net in the accompanying statement of operations. The SAFE has a valuation cap of $30.0 million and an 80% discount rate.

X
- Definition Technology Transfer Agreement + References No definition available. + Details
Name: | lsta_TechnologyTransferAgreementAbstract
Namespace Prefix: | lsta_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Technology Transfer Agreement + References No definition available. + Details
Name: | lsta_TechnologyTransferAgreementTextBlock
Namespace Prefix: | lsta_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration